Form 4: ONCY CBO Andrew Aromando Buys 29,600 Shares

ONCOLYTICS BIOTECH INC's Chief Business Officer, Andrew Aromando, acquired 29,600 common shares at a weighted average price of $0.8587.

Summary

• Andrew Aromando, Chief Business Officer of ONCOLYTICS BIOTECH INC, purchased 29,600 common shares.
• The shares were acquired on February 11, 2026, at a weighted average price of $0.8587 per share, with prices ranging from $0.85 to $0.86.
• The purchase was made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Mr. Aromando beneficially owns a total of 55,100 common shares of ONCOLYTICS BIOTECH INC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying typically indicates management confidence in the company's future prospects, although the size of the transaction is relatively small.

Positives

• Insider buying by a Chief Business Officer can signal confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as it is a report of a past insider transaction.

Industry Context

StockSavvy.ai notes that insider buying, especially by a Chief Business Officer, can sometimes be interpreted by the market as a positive signal, suggesting management's belief in the company's valuation or future performance. This transaction is specific to ONCOLYTICS BIOTECH INC and does not directly reflect broader industry trends, though it occurs within the biotechnology sector where company-specific developments often drive stock performance.

Comparison to Industry Standards

• This Form 4 reports an insider purchase, which is a standard disclosure for executive stock transactions. It does not provide financial results or operational metrics that can be directly compared to industry benchmarks or specific competitor projects. The significance lies in the insider's conviction rather than a performance comparison.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive indicator of management confidence, potentially influencing investor sentiment.

Key Dates

Recommendation

While the insider purchase by the Chief Business Officer is a positive signal, indicating management's confidence, this single transaction alone is not sufficient to warrant a 'buy' recommendation without further fundamental analysis of the company's financial health, strategic outlook, and broader market conditions. It suggests a 'hold' as a neutral stance, acknowledging the positive insider action but awaiting more comprehensive data.

Keywords

ONCOLYTICS BIOTECH INC, ONCY, Insider Trading, Form 4, Andrew Aromando, Share Purchase, Chief Business Officer, Equity Acquisition, Rule 10b5-1